ClinicalTrials.gg
Not yet recruitingNCT07219199Updated Sep 29, 2026

Residual IDH1-Mutant Tumor Cell Quantification Study

An interventional study of UR-ddPCR in Glioma, sponsored by NYU Langone Health. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Diagnostic

How we know

Updated Sep 29, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Glioma by NYU Langone Health — 3 open to participants now, 5 under way, none of them phase 3. Glioma · NYU Langone Health.

Planned enrollment
Largest of 11
105 · median 20
Started
2027
the only one that year
No phase
3 of 12
1 open now
Registered
11th of 12
by date

Among the 12 studies in Glioma by NYU Langone Health, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2027, is one of 3 with no phase, and was the 11th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

3 of the 12 studies in Glioma by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Glioma by NYU Langone Health, or all of them as a file.
02

Study summary

This is a single-site, single-arm, prospective, interventional cohort study using intraoperative ultra-rapid droplet digital polymerase chain reaction (UR- ddPCR) to assess residual IDH1-mutant tumor at the end of surgical resection and, if positive, guide additional resection in real-time.

03

Conditions studied

  • Glioma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at the time of consent (any sex)
  • Newly diagnosed diffuse glioma with either (a) radiographic features consistent with IDH-mutant glioma or (b) prior molecular confirmation of an IDH mutation
  • Scheduled for tumor tissue or surgical resection at NYU Langone Health

Exclusion criteria

Exclusion Criteria:

  • Active virus (HCV) infection or suspected/confirmed prion disease (e.g., Creutzfeldt-Jakob disease), as documented in the medical record or by the treating physician, due to biosafety and tissue- handling restrictions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    UR-ddPCR During Tumor Biopsy/Resection Procedure

    During the participant's tumor biopsy or resection, the neurosurgeon will perform maximal safe resection, as per standard clinical practice, and allocate nine tissue specimens (three from the core of the tumor and six from the tumor-brain interface) for UR-ddPCR testing. If both core and tumor-brain interface samples test positive and further removal is judged safe, the neurosurgeon may perform additional resection and obtain final specimens from the positive sites before concluding the surgery. Up to 15 tissue specimens may be collected and tested during the procedure. Postoperative care and clinical follow-up will proceed per standard of care.

    Device: UR-ddPCR

Interventions

  • DeviceUR-ddPCR

    The investigational UR-ddPCR assay will be performed on collected tissue specimens during the participant's scheduled surgical visit.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from surgery to the time of the first MRI demonstrating radiographic progression (using Response Assessment in Neuro-Oncology \[RANO\] criteria) or death due to any cause (whichever occurs earlier).

    Time frame: Up to Year 3 Post-Procedure

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from surgery to the time of death due to any cause (whichever occurs earlier).

    Time frame: Up to Year 3 Post-Procedure

  2. Residual Tumor Volume

    Assessed via MRI.

    Time frame: Postoperative Day 1 (POD1)

  3. Radiographic PFS

    Radiographic PFS is defined as the time from surgery to the time of the first MRI demonstrating radiographic progression (using Response Assessment in Neuro-Oncology \[RANO\] criteria).

    Time frame: Month 6 Post-Procedure, Month 12 Post-Procedure, Month 24 Post-Procedure, Month 36 Post-Procedure

  4. Time to Radiographic Recurrence

    Time to Radiographic Recurrence is defined as the time from surgery to the time of the first MRI demonstrating radiographic recurrence.

    Time frame: Up to Year 3 Post-Procedure

  5. Percent Change in Mutant Allele Fraction (MAF)

    Time frame: Post-Operative Day 0 (POD0), post-additional resection of tumor-brain interface samples (Up to Year 3)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2027; primary completion for Aug 2032, 60 months later.

Of 131 non-industry interventional studies with no phase under Glioma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 114. This study's planned 60 months is close to that.

Counting every sponsor, half of 142 studies reached it within 58 months; a quarter within 34 and three quarters within 114.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: start Dec 2025 → Aug 2027, primary completion Dec 2030 → Aug 2032 and completion Dec 2030 → Aug 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2025
First posted
Oct 21, 2025
StartEst.
Aug 2027was Dec 2025
Primary completionEst.
Aug 2032was Dec 2030
CompletionEst.
Aug 2032was Dec 2030
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 2025→Aug 2027
Sep 29, 2026
Primary completion
Dec 2030→Aug 2032
Sep 29, 2026
Study completion
Dec 2030→Aug 2032
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Start date Dec 2025→Aug 2027
    Primary completion Dec 2030→Aug 2032
    Study completion Dec 2030→Aug 2032
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07219199
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Oct 21, 2025
Start date
Aug 2027 (estimated)
Primary completion
Aug 2032 (estimated)
Completion
Aug 2032 (estimated)
Last update
Sep 29, 2026

Study contacts

Daniel Orringer, MD
Contact
Daniel.Orringer@nyulangone.org
(212) 263-0909
Daniel Orringer, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion